On this page
If you stop a GLP-1, the weight usually comes back. In the two trials built to answer this exact question, people regained a large share of what they’d lost within a year of stopping. The regain tracked the drug leaving their bodies, and it had nothing to do with willpower falling apart.
That’s the headline. Here’s the data behind it.
The two trials that measured stopping
Most GLP-1 trials measure how much weight you lose. In STEP 1 (Wilding et al., NEJM 2021, 1,961 adults), people on brand-name semaglutide (Wegovy) 2.4 mg lost 14.9% of their body weight on average by week 68. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), people on brand-name tirzepatide (Zepbound) lost as much as 20.9% by week 72. Two other trials asked the opposite question: what happens when you stop?
STEP 4 (Rubino et al., JAMA 2021) put everyone on brand-name semaglutide (Wegovy) for 20 weeks. Then it split them at random, so some kept going and some switched to placebo. The people who stopped regained much of what they’d lost, and the people who kept going didn’t.
SURMOUNT-4 (Aronne et al., JAMA 2024) did the same with brand-name tirzepatide (Zepbound) and put exact numbers on it. After stopping, people regained about 14% of their body weight over the next year, while the group that stayed on treatment lost another 5.5%. That’s a gap of nearly 20 percentage points of body weight in just twelve months.
Why the weight comes back
The rebound isn’t a character flaw showing up on schedule. It’s pharmacology.
GLP-1 medicines do three things. They slow gastric emptying (how fast food leaves your stomach). They act on the appetite centers in your brain. And they help your body release insulin when your blood sugar rises. Tirzepatide also works on a second hormone, called GIP. Together, these quiet your appetite and food noise while the drug is in you.
Every one of those effects depends on the drug being there. When it clears, your stomach empties faster again. Your appetite signals drift back toward where they were, and hunger returns. Then your body works to defend the fat mass it carried before.
So regain is the predictable result of removing the drug, the same way blood pressure climbs back after you stop a blood pressure pill. Obesity behaves like a chronic condition: it responds to treatment and comes back without it.
Stopping also gives up the heart and metabolic benefits you were building. SELECT (Lincoff et al., NEJM 2023, 17,604 patients) linked brand-name semaglutide (Wegovy) to a 20% relative drop in major heart events, and that was an effect seen while people were on treatment.
None of this makes stopping wrong. What drives the rebound is stopping without a plan.
What actually holds the loss
Three things matter, and they aren’t equal.
The biggest is staying on treatment. People who stay on the drug tend to avoid the rebound. Some people may not need the top dose forever, and a lower maintenance dose, set with your clinician, is one option. No trial has tested how well a lower dose holds the loss, though. Cost is often the real reason people quit, so it matters that a maintenance plan has a cash-pay option. Current prices for compounded semaglutide and tirzepatide are on each treatment page.
The second is muscle. DXA body-composition scans show that a real share of GLP-1 weight loss is lean mass. Less muscle lowers how much energy your body burns at rest, which makes the new weight harder to defend. The fix is strength training twice a week plus enough protein, with a target your clinician can help you set, and how to protect muscle while you lose covers the details. We don’t yet know how much that muscle loss matters for daily function over years, because the long-term data isn’t in.
The third is the exit itself. Whether to taper or stop outright, and how, is its own decision, and how to come off a GLP-1 walks through it.
The practical move
Plan your maintenance phase with your clinician before you change your dose, instead of waiting until the scale starts climbing. Staying on treatment is a fair choice too. It helps to decide your dose, your training, and your protein while the drug is still working. If you’re deciding whether to start, switch, or step down, the five-minute quiz matches your situation to a plan that a clinician reviews within 24 hours.
